ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2385

The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes

Billy Kim1, Ahmed Deeb1, Douglas Mintz1, Susan Goodman2, Jose Rodriguez2, Mark Figgie2 and Jason Blevins3, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2025

Keywords: Arthroplasty, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) patients seeking total knee arthroplasty (TKA) may present with secondary avascular necrosis (AVN) of the knee due to high-dose glucocorticoid use. Whether presence of AVN negatively impacts TKA outcomes in this high-risk population has not previously been studied.

Methods: A retrospective analysis of 184 knees (150 patients) with SLE undergoing TKA between 2015 and 2023 at a large academic institution was conducted. The cohort was stratified by the presence of AVN on preoperative X-ray and/or magnetic resonance imaging (MRI) when available. Imaging diagnosis was validated by an experienced musculoskeletal radiologist. Patient characteristics, clinical outcomes, and patient-reported outcome measures (PROMs) were compared between groups using univariable and multivariable analyses. Mean follow-up was 4.1 years (range: 0.1-8.5).

Results: AVN was present in 13% (n=23/184) of SLE knees. Patients with AVN were younger (P< 0.01) and had lower BMI than patients without AVN (P=0.05). Multivariable analyses demonstrated that younger age was associated with increased risk of 90-day readmission (P=0.03) and revision (P< 0.01). There were no significant differences in complication rates or postoperative PROMs between SLE patients with and without AVN (P >0.05). Based on osteonecrosis patterns on MRI, knee AVN was categorized into three sequential classes: I) primarily metadiaphyseal; II) metadiaphyseal with articular extension; III) progression with severe deformity or bone loss.

Conclusion: TKA outcomes in SLE patients with AVN are comparable to those without. Primary cemented implants provide durable results. In advanced stages of knee osteonecrosis, however, judicious preoperative evaluation is warranted, as significant bone deformities and defects may necessitate augments, cones, and/or stems.

Supporting image 1MRI patterns of osteonecrosis in SLE patients with AVN


Disclosures: B. Kim: None; A. Deeb: None; D. Mintz: American College of Radiology, 4, New York State Radiological Society, 4, Society of Skeletal Radiology, 4; S. Goodman: Johnson and Johnson, 2, Novartis, 5, Pfizer, 2; J. Rodriguez: ASS ASC Development Network, LLC, 8, BICMD, 2, 8, Exactech, Inc., 2, 9, HS2, LLC, 8, Joint Effort Administrative Services Organization, 8, Restor3d, 2, 9, Smith & Nephew, 2, 9, Wishbone, 8; M. Figgie: Bone Solutions, Inc, 2, Diffusion Rx, Inc., 1, 8, Enovis, 2, 9, HS2, LLC, 8, Icarus Medical, 8, Joint Effort Administrative Services Organization, 8, Mekanika, Inc., 8, Sylke, Inc., 1, 8, Wishbone Medical, 1, 2, 8, 9; J. Blevins: Globus Medical, 2, LimaCorporate, 2, Smith & Nephew, 2.

To cite this abstract in AMA style:

Kim B, Deeb A, Mintz D, Goodman S, Rodriguez J, Figgie M, Blevins J. The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-presence-of-avascular-necrosis-in-patients-with-systemic-lupus-erythematosus-undergoing-total-knee-arthroplasty-is-not-associated-with-worse-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-presence-of-avascular-necrosis-in-patients-with-systemic-lupus-erythematosus-undergoing-total-knee-arthroplasty-is-not-associated-with-worse-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology